X4 Pharmaceuticals, Inc (XFOR) Stock Research
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Latest price: 2.75 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| Craig Adam R | buy | 2026-10-16 | 11883.64 |
| KIRSKE DAVID | sell | 2026-10-01 | 33658.33 |
| Volpone John | sell | 2026-08-12 | 109228.03 |
| Craig Adam R | sell | 2026-08-12 | 210829.3 |
| KIRSKE DAVID | sell | 2026-06-30 | 36428.21 |
| KIRSKE DAVID | sell | 2026-05-12 | 72820.36 |